Last reviewed · How we verify
VX-661/Ivacaftor
VX-661/Ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector.
VX-661/Ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector. Used for Cystic fibrosis.
At a glance
| Generic name | VX-661/Ivacaftor |
|---|---|
| Also known as | VX-661+VX-770 |
| Sponsor | Vertex Pharmaceuticals Incorporated |
| Drug class | CFTR corrector |
| Target | CFTR |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
It works by correcting the function of the CFTR protein, which is responsible for transporting chloride ions across cell membranes. This helps to improve the function of the lungs and other organs in people with cystic fibrosis.
Approved indications
- Cystic fibrosis
Common side effects
- Nausea
- Vomiting
- Headache
- Diarrhea
- Abdominal pain
Key clinical trials
- Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older (PHASE3)
- Modulate-CF: Cystic Fibrosis Transmembrane Regulator (CFTR) Biomarker Study to Evaluate the Rescue of Mutant CFTR in Patients With Cystic Fibrosis Treated With CFTR-modulators
- Population Pharmacokinetics of Elexacaftor-tezacaftor-ivacaftor in a Paediatric Population
- Trikafta for Patients With Non-cystic Fibrosis Bronchiectasis (PHASE4)
- Personalized Theratyping Trial (EARLY_PHASE1)
- Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.
- Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del (PHASE3)
- Glucose Metabolism in Cystic Fibrosis Related Diabetes (CFRD)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VX-661/Ivacaftor CI brief — competitive landscape report
- VX-661/Ivacaftor updates RSS · CI watch RSS
- Vertex Pharmaceuticals Incorporated portfolio CI